Search
AS1409
go.drugbank.com/drugs/DB05182InvestigationalAS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.
Tetroxoprim
go.drugbank.com/drugs/DB15976ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity.
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870Experimentalwell as other pro-angiogenic growth factors. … during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), as
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalIt has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high. … ORG-34517 is currently under investigation by Organon for the treatment of depression.
Liranaftate
go.drugbank.com/drugs/DB19985ExperimentalLiranaftate is a small molecule drug. Liranaftate has a monoisotopic molecular weight of 328.12 Da.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseBepotastine
go.drugbank.com/drugs/DB04890ApprovedIt is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. … Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the
KP-1461
go.drugbank.com/drugs/DB05644InvestigationalKP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue.